公开(公告)号：US20240238300A1

公开(公告)日：2024-07-18

申请号：US18563058

申请日：2022-05-23

申请人： Jill KREMER ,  TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kei OGUCHI ,  Jill KREMER ,  Karim BENHADJI

IPC分类号： A61K31/519 ,  A61P35/00

CPC分类号： A61K31/519 ,  A61P35/00

摘要： A method of treating a subject with cancer having an aberration in EGFR and/or HER2, whereby the subject is administered 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N—((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240165120A1

公开(公告)日：2024-05-23

申请号：US18549249

申请日：2021-08-30

申请人： TAIHO PHARMACEUTICAL CO., LTD. ,  Karim BENHADJI

发明人： Karim BENHADJI ,  Volker WACHECK ,  Abdel HALIM

IPC分类号： A61K31/519 ,  A61K9/00 ,  A61P35/00 ,  C12Q1/6886

CPC分类号： A61K31/519 ,  A61K9/0053 ,  A61P35/00 ,  C12Q1/6886 ,  C12Q2600/156

摘要： A method of treating a subject with cholangiocarcinoma having a co-occurring genetic alteration in FGFR2 and a cancer driver gene selected from TP53, BAP1, ARID1A, MLL2, PIK3C2B, IKBKE, MCL1, MDM4, and MYC, whereby the subject is administered (S)-1-[(3)-[4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240025910A1

公开(公告)日：2024-01-25

申请号：US18253273

申请日：2021-11-18

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Isao MIYAZAKI ,  Satoru IGUCHI ,  Kentaro WAKAYAMA

IPC分类号： C07D487/04 ,  A61P35/00

CPC分类号： C07D487/04 ,  A61P35/00

摘要： An object to be solved of the present invention is to provide a brain-penetrable antitumor agent showing an excellent brain penetration property and RET inhibitory activity.
The present invention provides brain-penetrable antitumor agent including a compound represented by Formula (I) below or a salt thereof as an active ingredient:




wherein R1, R2, and R3 are as described in Specification.

公开(公告)号：US11857513B2

公开(公告)日：2024-01-02

申请号：US16345792

申请日：2017-10-31

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Kazutaka Miyadera ,  Yoshimi Aoyagi ,  Shinichi Hasako

IPC分类号： A61K31/519 ,  A61P35/00

CPC分类号： A61K31/519 ,  A61P35/00

摘要： An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.

公开(公告)号：US11786534B2

公开(公告)日：2023-10-17

申请号：US17430208

申请日：2020-02-14

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Fuyuki Yamamoto ,  Takashi Mizutani ,  Hidefumi Kasuga ,  Hirokazu Fuchida ,  Shoki Hara ,  Yu Kobayakawa ,  Yoshio Ogino

IPC分类号： A61K31/519 ,  C07D487/04 ,  A61K31/5377 ,  A61P35/00 ,  C07D519/00

CPC分类号： A61K31/5377 ,  A61K31/519 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

摘要： The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230285397A1

公开(公告)日：2023-09-14

申请号：US18016103

申请日：2021-07-14

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kei OGUCHI

IPC分类号： A61K31/519 ,  A61P35/00

CPC分类号： A61K31/519 ,  A61P35/00

摘要： Provided is a therapeutic agent for a disease associated with EGFR, the agent comprising a compound that has EGFR inhibitory activity and has brain penetration properties as an active ingredient. The present invention provides a compound represented by the formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the present specification, or a salt thereof, and a therapeutic agent for a disease associated with EGFR, the agent comprising a compound represented by the following formula (I), or a salt thereof as an active ingredient.

公开(公告)号：US11696917B2

公开(公告)日：2023-07-11

申请号：US16489212

申请日：2018-02-27

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Hiroki Irie ,  Kei Oguchi ,  Yayoi Fujioka

IPC分类号： A61K31/519 ,  A61P35/00 ,  A61K33/243 ,  A61K31/337 ,  A61K31/437 ,  A61K31/439 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/7068 ,  A61K45/06

CPC分类号： A61K31/519 ,  A61K31/337 ,  A61K31/437 ,  A61K31/439 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/7068 ,  A61K33/243 ,  A61K45/06 ,  A61P35/00

摘要： To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z1, Z2, Z3, Z4, W, n, R1, R2, and R3 have meanings as defined in the present specification, or a salt thereof and other antitumor agent(s) for combined administration.

公开(公告)号：US20230064254A1

公开(公告)日：2023-03-02

申请号：US17786504

申请日：2020-12-18

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Yasunobu ARIMA ,  Ryusuke KANEKO

IPC分类号： C07D487/04 ,  A61P13/12

摘要： [Problem] Provided is a novel therapeutic agent for chronic glomerulonephritis.
[Solution] A therapeutic agent for chronic glomerulonephritis comprising, as an active ingredient, a compound represented by the following general formula (I) or a salt thereof: [Selected Drawing] None

公开(公告)号：US20230055953A1

公开(公告)日：2023-02-23

申请号：US17788847

申请日：2020-12-25

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Risa Goto

IPC分类号： A61K39/39 ,  A61K38/16 ,  A61K47/65 ,  A61P35/00

摘要： The present invention provides an agent for adjuvant therapy of tumors that exerts remarkable inhibitory effects on tumor metastasis and recurrence while developing few side effects. The agent for adjuvant therapy comprises, as an active ingredient, a peptide having 4 linked CTL epitopes.

公开(公告)号：US20220411368A1

公开(公告)日：2022-12-29

申请号：US17775795

申请日：2020-11-13

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Hiroyuki NAKAMURA

IPC分类号： C07D207/14

摘要： A benzoic acid salt of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile is provided. A sorbic acid salt of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile is also provided.